Regeneron Pharmaceuticals Inc. Takes Position in bluebird bio, Inc. (NASDAQ:BLUE)

Regeneron Pharmaceuticals Inc. bought a new stake in bluebird bio, Inc. (NASDAQ:BLUE) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 21,000 shares of the biotechnology company’s stock, valued at approximately $175,000. bluebird bio makes up 0.0% of Regeneron Pharmaceuticals Inc.’s portfolio, making the stock its 6th largest holding.

Other institutional investors have also recently bought and sold shares of the company. Barclays PLC lifted its stake in bluebird bio by 273.7% in the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock valued at $130,000 after acquiring an additional 184,605 shares in the last quarter. Geode Capital Management LLC lifted its stake in bluebird bio by 3.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock valued at $2,433,000 after acquiring an additional 166,771 shares in the last quarter. State Street Corp lifted its stake in bluebird bio by 1.1% in the 3rd quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock valued at $1,996,000 after acquiring an additional 43,382 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in bluebird bio by 2,270.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock valued at $193,000 after acquiring an additional 355,562 shares in the last quarter. Finally, Verition Fund Management LLC bought a new stake in bluebird bio in the 3rd quarter valued at approximately $42,000. Institutional investors own 87.43% of the company’s stock.

bluebird bio Stock Down 1.5 %

BLUE stock opened at $3.94 on Tuesday. The company has a current ratio of 0.51, a quick ratio of 0.33 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $38.30 million, a PE ratio of -0.11 and a beta of 0.76. bluebird bio, Inc. has a 1-year low of $3.56 and a 1-year high of $33.20. The business’s 50 day simple moving average is $6.85 and its 200 day simple moving average is $8.51.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Royal Bank of Canada reiterated a “sector perform” rating and set a $80.00 price objective on shares of bluebird bio in a research note on Friday, November 15th. StockNews.com assumed coverage on bluebird bio in a research note on Tuesday, March 4th. They set a “sell” rating on the stock. Baird R W cut bluebird bio from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 21st. Barclays upped their price objective on bluebird bio from $2.00 to $40.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 31st. Finally, JPMorgan Chase & Co. upgraded bluebird bio from an “underweight” rating to a “neutral” rating in a research note on Monday, February 24th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $48.10.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.